AbbVie (NYSE:ABBV) Issues Q3 2026 Earnings Guidance

AbbVie (NYSE:ABBV) updated its third quarter 2026 earnings guidance on Friday. The company provided EPS guidance of 3.840-3.880 for the period, compared to the consensus estimate of 3.850. The company issued revenue guidance of $17.2 billion-$17.2 billion, compared to the consensus revenue estimate of $17.3 billion.

AbbVie Stock Performance

Shares of ABBV stock opened at $251.33 on Friday. The company has a market capitalization of $444.05 billion, a P/E ratio of 123.81, a price-to-earnings-growth ratio of 0.85 and a beta of 0.30. The company’s 50 day moving average price is $239.10 and its two-hundred day moving average price is $224.05. AbbVie has a 52 week low of $187.62 and a 52 week high of $267.47.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The firm had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.78 billion. During the same quarter in the previous year, the firm posted $2.97 earnings per share. The business’s revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts forecast that AbbVie will post 14.14 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. AbbVie’s dividend payout ratio is presently 340.89%.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on ABBV shares. Guggenheim boosted their price target on AbbVie from $249.00 to $261.00 and gave the company a “buy” rating in a report on Thursday, July 9th. Wells Fargo & Company lifted their target price on AbbVie from $260.00 to $295.00 and gave the company an “overweight” rating in a research report on Friday, July 10th. Morgan Stanley boosted their target price on AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a research report on Monday, June 8th. Finally, JPMorgan Chase & Co. raised their price target on shares of AbbVie from $260.00 to $280.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and a consensus target price of $269.29.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Solid second-quarter results: AbbVie reported adjusted EPS of $3.65, above the $3.60 consensus estimate, while revenue rose 10.2% year over year to $16.99 billion. Reuters article
• Positive Sentiment: Immunology and neuroscience remained growth drivers: Skyrizi revenue reached $5.505 billion and Rinvoq generated $2.525 billion, while neuroscience revenue increased 20.3% to $3.228 billion. Botox also showed signs of stabilization, supporting the company’s diversified growth profile. AbbVie earnings release
• Positive Sentiment: Pipeline and portfolio expansion: AbbVie is advancing a global Phase 2/3 combination study in acute myeloid leukemia and recently received European approval for Rinvoq in severe alopecia areata, adding potential long-term growth opportunities. AML trial article
• Neutral Sentiment: Near-term guidance was broadly in line: Third-quarter adjusted EPS guidance of $3.84–$3.88 brackets the $3.85 consensus estimate, but revenue guidance of approximately $17.2 billion is slightly below the $17.3 billion analyst forecast.
• Negative Sentiment: Full-year EPS outlook was reduced: AbbVie lowered 2026 adjusted EPS guidance to $13.87–$14.07 from $13.91–$14.11. The revised range includes an estimated $0.14-per-share dilution from the planned $10.9 billion acquisition of Apogee Therapeutics, pushing the midpoint below Wall Street expectations. Zacks guidance article
• Negative Sentiment: Acquisition and execution concerns weigh on sentiment: Investors are balancing Apogee’s potential to strengthen AbbVie’s immunology pipeline against its immediate earnings dilution, while oncology revenue fell 1.5% and aesthetics revenue was essentially flat during the quarter.

Institutional Trading of AbbVie

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of Jackson Hole Trust grew its stake in AbbVie by 0.6% in the fourth quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company’s stock valued at $1,648,000 after purchasing an additional 44 shares in the last quarter. Imprint Wealth LLC boosted its holdings in shares of AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after buying an additional 45 shares during the last quarter. one8zero8 LLC grew its stake in shares of AbbVie by 0.5% in the fourth quarter. one8zero8 LLC now owns 9,825 shares of the company’s stock valued at $2,245,000 after buying an additional 50 shares in the last quarter. Papamarkou Wellner Asset Management inc. increased its holdings in AbbVie by 0.5% during the fourth quarter. Papamarkou Wellner Asset Management inc. now owns 9,611 shares of the company’s stock worth $2,196,000 after buying an additional 52 shares during the last quarter. Finally, Twin Focus Capital Partners LLC raised its position in AbbVie by 5.6% during the fourth quarter. Twin Focus Capital Partners LLC now owns 1,082 shares of the company’s stock worth $247,000 after acquiring an additional 57 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.